GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » Total Current Liabilities

Provention Bio (Provention Bio) Total Current Liabilities : $90.39 Mil (As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Provention Bio Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Provention Bio's total current liabilities for the quarter that ended in Dec. 2022 was $90.39

Provention Bio Total Current Liabilities Historical Data

The historical data trend for Provention Bio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio Total Current Liabilities Chart

Provention Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
Get a 7-Day Free Trial 1.87 3.84 16.73 22.79 90.39

Provention Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.79 27.05 25.15 25.12 90.39

Provention Bio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Provention Bio's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=65.41+0
+Other Current Liabilities+Current Deferred Liabilities
=7.294+17.686
=90.39

Provention Bio's Total Current Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=65.41+0
+Other Current Liabilities+Current Deferred Liabilities
=7.294+17.686
=90.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Provention Bio Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Provention Bio's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Provention Bio (Provention Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » Total Current Liabilities
Comparable Companies
TNYA CYDY ACBM LXRX FDMT LQDA ANTX DYN ADAP ALVR OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701
Website
https://www.proventionbio.com
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.
Executives
Sessa Capital (master), L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer director, 10 percent owner, officer: President and CEO PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon director, 10 percent owner, officer: Chief Scientific Officer C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel officer: Chief Accounting Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien officer: Chief People Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi officer: Chief Operations Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio officer: Chief Quality Officer ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos officer: Chief Medical Officer & COO ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche officer: Chief Financial Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701